Karyopharm Therapeutics Inc. (KPTI)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Karyopharm Therapeutics Inc. reported revenue of $146.07M, up 0.6% from the prior year. The company ran a net loss, with a net margin of -134.2%. It held $108.42M in total assets against $401.34M in total liabilities.
Key ratios (FY2025)
-62.1%
Operating margin
-134.2%
Net margin
+0.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.07M | $145.24M | $146.03M | $157.07M | $209.82M | $108.08M | $40.89M | $30.34M | $1.60M | $154.0K |
| Operating Income | -$90.71M | -$119.44M | -$129.54M | -$142.20M | -$98.27M | -$171.85M | -$189.28M | -$179.88M | -$130.54M | -$110.73M |
| Net Income | -$196.04M | -$76.42M | -$143.10M | -$165.29M | -$124.09M | -$196.27M | -$199.59M | -$178.41M | -$128.98M | -$109.58M |
| EPS (Diluted) | $-17.93 | $-14.00 | $-18.79 | $-2.02 | $-1.65 | $-2.72 | — | — | — | — |
| Total Assets | $108.42M | $164.42M | $240.44M | $358.17M | $305.31M | $313.05M | $294.96M | $341.19M | $180.29M | $180.38M |
| Total Liabilities | $401.34M | $350.44M | $376.64M | $374.83M | $384.98M | $262.50M | $245.19M | $158.02M | $50.83M | $18.14M |
| Shareholders' Equity | -$292.93M | -$186.02M | -$136.21M | -$16.66M | -$79.67M | $50.55M | $49.77M | $183.17M | $129.46M | $162.24M |
| Cash & Equivalents | $60.54M | $62.48M | $52.23M | $135.19M | $190.46M | $85.92M | $128.86M | $118.02M | $69.00M | $49.66M |
| Operating Cash Flow | -$75.37M | -$127.49M | -$92.72M | -$149.55M | -$107.12M | -$160.23M | -$190.82M | -$159.12M | -$73.72M | -$84.39M |
| Capital Expenditures | $0 | $142.0K | $0 | $118.0K | $212.0K | $145.0K | $206.0K | $2.36M | $62.0K | $70.0K |
| Shares Outstanding | 18.31M | 8.41M | 114.92M | 113.21M | 75.75M | 73.92M | 65.37M | 60.83M | 49.53M | 41.89M |